When setup takes a week but the PO takes six months
In the last few weeks, three separate prospects reached out to us in what looked like sudden bursts of interest.
AI can’t reason with context it doesn’t have
A question we hear often from biopharma leadership and investors: "With AI improving this fast, do we really need
The biggest barrier to modernizing biopharma?
There's a harmful posture across biopharma that is hampering meaningful progress: a belief that certain categories of work
Lessons from onboarding
Most onboarding journeys hit an early inflection point: a moment when it becomes clear whether the software will actually stick.
A premium for partnership, rather than features
When your timelines are measured in years rather than weeks - as they are in the biopharma world - partnership
Is biotech losing its best talent to AI?
The right technical people can be a huge competitive advantage in industries like biopharma. The challenge becomes attracting and retaining
Where is your biotech on the data maturity ladder?
Two biotech companies, both developing promising therapeutics with strong scientific teams. In a board meeting, someone asks: "where do
Death by democracy
We had a call this month with an SVP who's taken 11 compounds into clinic, across 6 biotechs.
Federated data lakes in biopharma: why “just put everything in one place” doesn’t work.
In most biopharma organizations, the data story is the same.
You have information scattered across every imaginable system: LIMS, ELNs,
The case for R&D observability
Why is it so hard to get answers to pretty straightforward questions, when it comes to biotech data? And what
